Form 4: Akero Director Judy Chou Converts Equity Post-Novo Nordisk Merger

Akero Therapeutics Director Judy Chou converted her restricted stock units and stock options into cash and contingent value rights following the merger with Novo Nordisk.

Summary

• Judy Chou, a Director of Akero Therapeutics, Inc. (AKRO), reported the disposal of her beneficial ownership in the company's securities.
• The transactions occurred on December 9, 2025, which was the effective date of the merger between Akero Therapeutics, Inc. and NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S.
• Pursuant to the Merger Agreement dated October 9, 2025, Akero Therapeutics became a wholly-owned subsidiary of Novo Nordisk A/S.
• 9,398 Restricted Stock Units (RSUs) held by Ms. Chou were deemed fully vested and cancelled, converting into a right to receive $54.00 in cash (Closing Consideration) and one Contingent Value Right (CVR) for each RSU.
• Multiple compensatory stock options, totaling 82,000 shares, were also deemed fully vested and cancelled.
• These stock options converted into a right to receive a cash payment equal to the product of the excess of the $54.00 Closing Consideration over the option's exercise price, multiplied by the number of shares subject to the option, plus one CVR for each share.
• The CVRs represent a right to receive an additional $6.00 in cash if a specified milestone is achieved, without interest and subject to withholding taxes.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person as their equity was successfully converted into cash and a potential future payment, indicating a favorable outcome from the merger for the insider.

Positives

• The reporting person received a significant cash payment for her equity holdings in Akero Therapeutics, reflecting the successful completion of the merger.
• The inclusion of Contingent Value Rights (CVRs) provides an opportunity for additional future cash payments if a specified milestone is met, aligning the reporting person's interests with potential future success of the acquired assets.

Negatives

• The reporting person no longer holds direct equity ownership in Akero Therapeutics, Inc., as it is now a wholly-owned subsidiary of Novo Nordisk A/S.

Risks

• The payment of $6.00 per CVR is contingent upon the achievement of a specified milestone, meaning this portion of the consideration is not guaranteed.

Future Outlook

The future outlook for the reporting person includes the potential to receive an additional $6.00 per Contingent Value Right (CVR) if a specified milestone related to the acquired Akero assets is achieved by Novo Nordisk.

Industry Context

This Form 4 filing reflects the finalization of a significant merger and acquisition event in the biopharmaceutical industry, where a larger pharmaceutical company, Novo Nordisk, acquired Akero Therapeutics. Such transactions are common as larger players seek to expand their pipelines, particularly in promising therapeutic areas like metabolic diseases, which Akero was focused on. The structure of the deal, including CVRs, is also a common mechanism to share future risks and rewards in biotech M&A.

Stakeholder Impact

• Shareholders of Akero Therapeutics, including the reporting person, received cash consideration and Contingent Value Rights (CVRs) for their shares/equity awards as part of the merger agreement.

Next Steps

• Potential future payment of $6.00 per CVR if a specified milestone is achieved by Novo Nordisk related to the acquired Akero assets.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Acquisition, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals